Over 1,000 Chemotherapy Protocols And Counting

Prospectively Randomized , phase 3 trial Treatment naïve Waldenström's macroglobulinemia (WM) Bortezomib, dexamethasone, rituximab, and cyclophosphamide (B-DRC ) vs. DRC

10 Jan

Multiple Myeloma

New Drug: Teclistamab in R/R Multiple Myeloma

Single-arm, multi-cohort, open-label, multicenter, phase 1/2 study Relapsed or refractory myeloma after at least three therapy lines (n=165) Teclistamab sc weekly

10 Jan

Biliary Tract Cancer

New Drug: Futibatinib for Cholangicarcinoma

A single-arm, multicenter, phase 2 study Advanced/metastatic unresectable iCCA harboring FGFR2 gene fusions Disease progression after ≥1 line of systemic therapy Futibatinib 20 m

20 Aug

Renal Cell Carcinoma

New Reference: Pembrolizumab and Lenvatinib for Advanced Non-Clear-Cell RCC

Single-arm, open-label, multicenter, phase II trial Previously untreated stage IV non-clear cell renal cell carcinoma Pembrolizumab + Lenvatinib (n=158

16 Jul

Colorectal Cancer

New Indication: Pembrolizumab for MSI-High Colorectal Cancer

Randomised, open-label, phase 3 study (KEYNOTE-177) Untreated microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer Pembrolizumab 200 mg every 3

15 Mar

Colorectal Cancer

New Indication: Encorafenib, Binimetinib, and Cetuximab for bRAF V600E Mutant Colorectal Cancer

Single-arm, multicenter, Phase-2 trial Previosly untreated, BRAF V600E mutant Colorectal cancer Encorafenib + Binimetinib + Cetuximab q28 (n=95)

15 Mar

Uterine Cancer

New Drug: Dostarlimab for Endometrial Cancer

Multicenter, multicohort, open-abel trial (GARNET) dMMR recurrent or advanced endometrial cancer who had progressed on or after a platinum-containing regimen Dostarlimab-gxly q21 (

15 Mar

Breast Cancer

New Indication: Sacituzumab Govitecan for HR+, her2 Negative Breast Cancer

Multicenter, randomized, open-label, phase III Unresectable locally advanced or metastatic HR-positive, HER2-negative breast cancer whose disease progressed after a CDK 4/6 inhibit

Easiest Access to Our Chemotherapy Protocol Library

Download our mobile app on iOS or Android to easily access our cancer protocol library, calculate chemotherapy doses, staging library, and access to the reference summaries